Canada Gazette, Part I, Volume 159, Number 9: GOVERNMENT NOTICES

March 1, 2025

DEPARTMENT OF CANADIAN HERITAGE

DEPARTMENT OF CANADIAN HERITAGE ACT

Notice of annual fee adjustment

Notice is hereby given that the Minister of Canadian Heritage, pursuant to section 10 and subsection 11(2) of the Department of Canadian Heritage Act and in compliance with sections 16 and 17 of the Service Fees Act, has revised fees for certain services provided by the Canadian Audio-Visual Certification Office (CAVCO).

The revised fees as of March 31, 2025, are listed below.

Table 1: Revised fees — Canadian Film or Video Production Tax Credit
Fee category	Fee as of March 31, 2025
Canadian film or video production certificate (Part A)	0.15% of eligible production cost
Certificate of completion (Part B)	0.15% of eligible production cost
Application for both certificates (parts A and B)	0.30% of eligible production cost (minimum: $239.75)
Amended certificate	$359.75
Certified copy	$100

Table 2: Revised fees — Film or Video Production Services Tax Credit
Fee category	Fee as of March 31, 2025
Accreditation certificate	$5,995
Amended certificate	$1,199
Certified copy	$100

The application fee for a Canadian film or video production certificate (0.15% of eligible production cost), the application fee for a certificate of completion (0.15% of eligible production cost), and the application fee if both certificates are requested at the same time (0.30% of eligible production cost) are exempt from an annual adjustment. These fees are based on a percentage of a production’s eligible production costs; therefore, they self-adjust for inflation.

The Canadian Film or Video Production Tax Credit (CPTC) and Film or Video Production Services Tax Credit (PSTC) certified copy fees ($100) are exempt from the annual fee adjustment, as they are considered “low-materiality fees” as per the Service Fees Act.

Any inquiries or comments about the revised fees can be directed to CAVCO, 1‑888‑433‑2200 (telephone) or bcpac-cavco@pch.gc.ca (email).

DEPARTMENT OF CROWN-INDIGENOUS RELATIONS AND NORTHERN AFFAIRS

MAA-NULTH FIRST NATIONS FINAL AGREEMENT

Notice of amendments to the Maa-nulth First Nations Final Agreement — Additions to Maa-nulth First Nation Lands of Huu-ay-aht First Nations (Appendix B)

Pursuant to 2.10.25 of the Maa-nulth First Nations Final Agreement (the “Final Agreement”), the following parcels of land, collectively referred to as the “Sarita River Lands and Anacla Lands,” became the Maa-nulth First Nation Lands of the Huu-ay-aht First Nations on February 6, 2023:

Parcel Identifier (PID) 007-728-425 (the east half of the northeast quarter of Section 14, Township 4, Barclay District);
PID 007-728-042 (the northwest quarter of Section 13, Township 4, Barclay District);
PID 007-728-263 (the west half of the northeast quarter of Section 13, Township 4, Barclay District);
PID 007-726-716 (the southwest quarter of Section 16, Township 1, Barclay District, except Plans VIP65991 and EPP123173);
PID 006-557-317 (fractional southwest quarter of Section 9, Township 1, Barclay District, except that Part in Plan 44819);
PID 007-727-500 (the southeast quarter of Section 17, Township 1, Barclay District, except Plan EPP 123172); and
PID 007-727-488 (the northwest quarter of Section 9, Township 1, Barclay District, except Part in Plan VIP65991 and VIP81007).

Appendix B-1, Part 2, Additional Lands Index and Appendix B-1, Part 2(a), Plans 6, 9, 12 and 13 of the Final Agreement, are therefore deemed to be amended and a new plan labelled Plan 14 has been added to Appendix B-1, Part 2(a), all as set out in the attached appendices to reflect the additions of the Sarita River Lands and Anacla Lands to the Maa-nulth First Nation Lands of the Huu-ay-aht First Nations.

Unless otherwise defined, capitalized terms used herein shall have the meanings ascribed to them in the Final Agreement.

Appendix B-1, Part 2

Figure 1: Additional Lands Index

Figure 1: Additional Lands Index – Text version below the map

Figure 1: Additional Lands Index - Text version

The map of the Additional Lands Index of Appendix B-1 Part 2, depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the southeast of the Imperial Eagle Channel, south of Alberni Inlet, north of Pacific Rim National Park Reserve, and surrounding Bamfield. This map also reflects additions to the Maa-nulth First Nation Lands of Huu-ay-aht First Nations after the Effective Date of the Maa-nulth First Nations Final Agreement.

The map of the Additional Lands Index includes a legend that lists the following: Additional Lands, Former Indian Reserves of Huu-ay-aht First Nations, Excluded Crown Corridors, Provincial Protected Area, Federal Protected Area, Municipality, Water Body, Watercourse and Highway. The Additional Lands Index also shows the highway to Ucluelet, the municipality of Ucluelet and the federally protected areas of Pacific Rim National Park Reserve.

The Additional Lands Index includes Plans 1 to 14. The Additional Lands Index map has red boxes around each plan area, and each plan has an associated map which is depicted in greater detail. Plan 1 is along the mid-left border of the map. Plan 2 is located in the middle of the Trevor Channel, south of Tzartus Island. Plan 3 is east of Plan 2, and Plan 4 is south of Plan 2. To the east of Plan 4 is Plan 5, and to the south of Plan 4 is Plan 6. Plan 7 is east of Plan 6. Plan 8 is above this collection of Plans, in the upper tip of the Trevor Channel and to the east of Tzartus Island. To its east is a row of Plans: Plan 9, Plan 10, and Plan 11. Below this row is Plan 12 (starting directly under Plan 9) and to its east is Plan 13 (directly under Plan 10). Plan 14 is located below Plan 6, overlapping with the northern part of Pachena Bay and Pachena River, which is depicted in the bottom left corner of this map. Pacific Rim National Park Reserve is a federal protected area, depicted in dark green, and some of these lands are located in the bottom left and bottom right corners of the map. Provincial protected areas are depicted in light green and include Klanawa River Ecological Reserve, Hitchie Creek Park, Nitinat Lake Ecological Reserve, and Baeria Rocks Ecological Reserve.

This map and its detailed descriptions are not to be used for defining Maa-nulth First Nation Lands boundaries or for their legal descriptions. Depictions of Maa-nulth First Nation Lands on this map and the lands’ detailed descriptions are to be used for illustrative purposes only.

Appendix B-1, Part 2(a)

Figure 2: Poett Nook / Sugsaw Plan 6

Figure 2: Poett Nook / Sugsaw Plan 6 – Text version below the map

Figure 2: Poett Nook / Sugsaw Plan 6 - Text version

The map of Poett Nook / Sugsaw, Plan 6 of Appendix B-1 Part 2(a), depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the east of the Bamfield Inlet and Bamfield, south of Trevor Channel, north of Pachena Bay and Pacific Rim National Park Reserve, and west of Pachena Lake.

This map includes a legend that lists the following: Subject Lands, Former Indian Reserve, Excluded Crown Corridors, UTM Coordinate, Primary Survey Parcel, Subdivision Parcel, Provincial Protected Area, Federal Protected Area, Municipality, Road (Paved), Road (Gravel), Electrical Transmission Line, Pipeline, Water Body and Watercourse.

Subject Land areas are depicted in yellow with a black border, and includes three Sites: Site 1 in the top right corner and right side of the map (including District Lot 826 and Block C Section 21, 22 and 28, TP1 and District Lot 825 and 826 of Plan EPC1927), Site 2 located in the upper left corner (including Block A, section 21, TP1 and Parcel D of the northeast quarter of Section 20, TP1 of Plan EPP6621), and part of Site 3 located at the bottom of the map.

Former Indian Reserves are depicted in grey with a purple border, and include Sachsa Former Indian Reserve 4, which is surrounded by Grappler Inlet on the west and by Site 1 Subject Lands on the south, east and part of the north borders.

One Excluded Crown Corridor, Plan EPC123172, is located at the bottom of the map through Site 3 Subject Lands.

Primary Survey Parcels and Subdivision Parcels of Vancouver Island are depicted in white with a black border, comprising most of the map, with Water Bodies and Water Courses embedded throughout. Water Bodies include Bamfield Inlet located at the upper left border of the map, Grappler Inlet in the upper middle of the map, and Calamity Lake in the middle of the map.

This map and its detailed descriptions are not to be used for defining the boundaries or legal descriptions of the Maa-nulth First Nation Lands of Huu-ay-aht First Nations. Depictions of the lands on this map and the lands’ detailed descriptions are to be used for illustrative purposes only.

Figure 3: Sarita / Carnation Creek Plan 9

Figure 3: Sarita / Carnation Creek Plan 9 – Text version below the map

Figure 3: Sarita / Carnation Creek Plan 9 - Text version

The map of Sarita / Carnation Creek, Plan 9 of Appendix B-1 Part 2(a), depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the east of the Trevor Channel, south of Alberni Inlet, north of other Subject Lands in Plan 12 and Sarita River, and northwest of Sarita Lake.

Subject Land areas are depicted in yellow with a black border, and include two Sites: Site 1 in the map’s bottom right-hand corner, and Site 2 starting from the map’s bottom left-hand corner with diagonal coverage to the map’s centre. Site 1 includes Block A District Lot 807 Plan EPC1508, Block F District Lot 80 Plan EPC1163, Block I District Lot 807 Plan EPC1508, and the east half of the northeast quarter and the northwest quarter of section 13, TP4. Site 2 includes Block A District Lot 802 Plan EPC833 and District Lot 803 Plan EPC875.

Former Indian Reserves are depicted in grey with a purple border, and include Formerly Numukamis Indian Reserve 1 located at the bottom left corner of the map, surrounded by Site 2 Subject Lands and other primary survey parcels or subdivision parcels in the north, and by Site 1 Subject Lands east.

Excluded Crown Corridors include Sarita Road and R07657 within Site 1, and Carnation Create Road and Numukamis Road within Site 2.

Primary Survey Parcels and Subdivision Parcels of Vancouver Island are depicted in white with a black border, comprising most of the map, with Water Bodies and Water Courses embedded throughout. Water Bodies include San Mateo Bay in the top left corner of the map, May Lake right below, and Consinka Lake located near the top middle of the map.

Figure 4: Sarita Plan 12

Figure 4: Sarita Plan 12 – Text version below the map

Figure 4: Sarita Plan 12 - Text version

The map of Sarita, Plan 12 of Appendix B-1 Part 2(a), depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the east of the Trevor Channel, south of lands in Plan 9, and west of the lands in Plan 13 and the Sarita Lake.

Subject Land areas are depicted in yellow with a black border, including two sites. The areas of Site 1 comprise the top half and right of the map. Site 1 includes many District Lots, including District Lot 805 (from Block D, E, F, and G) and District Lot 806 (from Block H), which are both further depicted in the Inset 2 at the top left corner of the map. Site 1 also includes District Lots 807 and 808 (from Block A). Subject Land area of Site 2 is depicted at the bottom of Formerly Numukamis Indian Reserve 1, located at the left middle of the map, which is further depicted in Inset 1 located at the bottom of the map.

Former Indian Reserves are depicted in grey with a purple border, and include Formerly Numukamis Indian Reserve 1 located at the top left corner of the map, surrounded by Site 1 Subject Lands on the east and south, and other primary survey parcels or subdivision parcels in the south.

Excluded Crown Corridors include R07656 (Bamfield B and Bamfield C), R07657, Blenheim Main, and Sarita Road.

Primary Survey Parcels and Subdivision Parcels of Vancouver Island are depicted in white with a black border, comprising the bottom and bottom left and top middle of the map, with the Water Bodies and the Sarita River Water Course embedded throughout.

Figure 5: Sarita Plan 13

Figure 5: Sarita Plan 13 – Text version below the map

Figure 5: Sarita Plan 13 - Text version

The map of Sarita, Plan 13 of Appendix B-1 Part 2(a), depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the north of Pacific Rim National Park Reserve, to the South of Plan 10 of Appendix B-1 Part 2(a) and Alberni Inlet, and to the east of Sarita River.

Subject Land areas are depicted in yellow with a black border, and include Site 1 with District Lots 807, 808, and 810 (within Block A) located in the top left corner of the map. The rest of the map includes Primary Survey Parcels or Subdivision Parcels of Vancouver Island, with Water Bodies and Watercourses embedded throughout. Water Bodies include the Klanawa River at the bottom right corner of the map, and Bewlay Lake and Sarita Lake in the upper left corner of the map.

One Excluded Crown Corridor runs throughout Site 1, which is R07656 (Bamfield C).

Figure 6: Poett Nook / Sugsaw Plan 14

Figure 6: Poett Nook / Sugsaw Plan 14 – Text version below the map

Figure 6: Poett Nook / Sugsaw Plan 14 - Text version

The map of Poett Nook / Sugsaw, Plan 14 of Appendix B-1 Part 2(a), depicts various areas within the Maa-nulth First Nation Lands of Huu-ay-aht First Nations, located in British Columbia to the southeast of Bamfield, the south of Plan 6 of Appendix B-1 Part 2(a) and to the north of much of the Pacific Rim National Park Reserve.

Subject Land areas are depicted in yellow with a black border, including Site 3 (the southeast quarter, southwest quarter, northwest quarter, and part of the southwest quarter) in the top left of the map. An Excluded Crown Corridor, Bamfield Road (Plan EPC123172 and Plan EPC123173) runs throughout Site 3.

Former Indian Reserve lands are depicted in grey with a purple border, and this map includes Formerly Anacla Indian Reserve 12 located at the top left corner of the map surrounded by the Site 3 Subject Land area in the north and partly in the east, Pacific Rim National Park Reserve in the east and west borders, and Pachena Bay in the south border with the Pachena River flowing diagonally from the bottom left corner to the top right of the Formerly Anacla Indian Reserve 12. Pachena Bay is a Water Body located at the bottom left corner of the map, the Pachena River is a Water Course embedded throughout, and Black Lake is a Water Body at the map’s bottom middle border. All Water Bodies and Water Courses are depicted in blue.

Federal Protected Areas are depicted in green, which include Pacific Rim National Park with parcels on the map’s upper left border, and just below the Site subject lands and on the east of Pachena Bay.

The rest of the map includes Primary Survey Parcels or Subdivision Parcels of Vancouver Island, Watercourses and Roads (Gravel) embedded throughout.

DEPARTMENT OF THE ENVIRONMENT DEPARTMENT OF HEALTH

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Publication after assessment of 14 substances in the Tricyclic Sesquiterpenes and Triterpenoids Group specified on the Domestic Substances List (section 77 of the Canadian Environmental Protection Act, 1999)

Whereas a summary of the draft assessment conducted on 14 substances identified in the annex below pursuant to paragraphs 68(b) and (c) of the Canadian Environmental Protection Act, 1999 is annexed hereby;

And whereas it is proposed to conclude that cedarwood oil, Texan cedarwood oil, enoxolone, mimosa oil, and ivy extract meet one or more of the criteria set out in section 64 of the Act,

Notice therefore is hereby given, for the purposes of paragraph 77(1)(a), that the Minister of the Environment and the Minister of Health (the ministers) propose to recommend to Her Excellency the Governor in Council that these substances be added to Part 2 of Schedule 1 to the Act.

Notice is furthermore given that the ministers have released a risk management scope document for these substances to initiate discussions with stakeholders on the development of risk management options.

And whereas it is proposed to conclude that alpha-cedrene, thujopsene, alpha-gurjunene, beta-patchoulene, beta-cedrene, T&T cedarwood oil, amboryl acetate, allantoin glycyrrhetinic acid, and American ginseng extract do not meet any of the criteria set out in section 64 of the Act,

Notice therefore is hereby given, for the purposes of paragraph 77(1)(a), that the ministers propose to take no further action on these nine substances at this time.

Public comment period — March 1, 2025, to April 30, 2025

Any person may, within 60 days after publication of this notice, file with the Minister of the Environment written comments on the measure the ministers propose to take and on the scientific considerations on the basis of which the measure is proposed. More information regarding the scientific considerations may be obtained from the Canada.ca (Chemical substances) website. The draft assessment and the risk management scope documents may also be consulted.

How to participate: All comments must cite the Canada Gazette, Part I, and the date of publication of this notice and be sent to the Executive Director, Substance Prioritization, Assessment and Coordination Division, Department of the Environment, Gatineau, Quebec K1A 0H3,

by email to substances@ec.gc.ca; or
by using the online reporting system available through Environment and Climate Change Canada’s Single Window.

In accordance with section 313 of the Canadian Environmental Protection Act, 1999, any person who provides information in response to this notice may submit with the information a request that it be treated as confidential. The request must provide reasons as provided for under subsection 313(2) of the Act.

Jacqueline Gonçalves
Director General
Science Reporting and Assessment Directorate
On behalf of the Minister of the Environment

Jacinthe David
Director General
Industrial Sectors and Chemicals Directorate
On behalf of the Minister of the Environment

Greg Carreau
Director General
Safe Environments Directorate
On behalf of the Minister of Health

ANNEX

Summary of the draft assessment of 14 substances in the Tricyclic Sesquiterpenes and Triterpenoids Group

Pursuant to section 68 of the Canadian Environmental Protection Act, 1999 (CEPA), the Minister of the Environment and the Minister of Health have conducted an assessment of 14 substances hereinafter referred to as the Tricyclic Sesquiterpenes and Triterpenoids Group. The Chemical Abstracts Service Registry Numbers (CAS RNs^{footnote 1}), the subgroups, the Domestic Substances List (DSL) names, and the common names of these substances that are used in this assessment are listed in the table below.

Table: Substances in the Tricyclic Sesquiterpenes and Triterpenoids Group
CAS RN	Subgroup	DSL name	Common name
469-61-4	Tricyclic Sesquiterpene subgroup 1	1H-3a,7-Methanoazulene, 2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-, [3R-(3α,3aβ,7β,8aα)]-	Alpha-cedrene
470-40-6	Tricyclic Sesquiterpene subgroup 1	Cyclopropa[d]naphthalene, 1,1a,4,4a,5,6,7,8-octahydro-2,4a,8,8-tetramethyl-, [1aS-(1aα,4aβ,8aR)]-	Thujopsene
489-40-7	Tricyclic Sesquiterpene subgroup 1	1H-Cycloprop[e]azulene, 1a,2,3,4,4a,5,6,7b-octahydro-1,1,4,7-tetramethyl-, [1aR-(1aα,4α,4aβ,7bα)]-	Alpha-gurjunene
514-51-2	Tricyclic Sesquiterpene subgroup 1	4,7-Methanoazulene, 1,2,3,4,5,6,7,8-octahydro-1,4,9,9-tetramethyl-, [1S-(1α,4α,7α)]-	Beta-patchoulene
546-28-1	Tricyclic Sesquiterpene subgroup 1	1H-3a,7-Methanoazulene, octahydro-3,8,8-trimethyl-6-methylene-, [3R-(3α,3aβ,7β,8aα)]-	Beta-cedrene
8000-27-9^{table b1 note a}	Tricyclic Sesquiterpene subgroup 1	Oils, cedarwood	Cedarwood oil
68608-32-2^{table b1 note a}	Tricyclic Sesquiterpene subgroup 1	Terpenes and Terpenoids, cedarwood-oil	T&T cedarwood oil
68990-83-0^{table b1 note a}	Tricyclic Sesquiterpene subgroup 1	Oils, cedarwood, Texan	Texan cedarwood oil
59056-62-1	Individual (Tricyclic Sesquiterpene)	2,3b-Methano-3bH-cyclopenta[1,3]cyclopropa[1,2]benzene-4-methanol, octahydro-7,7,8,8-tetramethyl-, acetate	Amboryl acetate
471-53-4	Triterpenoid subgroup 2	Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3β,20β)-	Enoxolone
4572-09-2^{table b1 note a}	Triterpenoid subgroup 2	Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3β,20β)-, compd. with (2,5-dioxo-4-imidazolidinyl)urea (1:1)	Allantoin glycyrrhetinic acid
8031-03-6^{table b1 note a}	Individual (Triterpenoid)	Oils, mimosa	Mimosa oil
84082-54-2^{table b1 note a}	Individual (Triterpenoid)	Ivy, Hedera helix, ext.	Ivy extract
90045-38-8^{table b1 note a}	Individual (Triterpenoid)	Ginseng, Panax quinquefolium, ext.	American ginseng extract
Table b1 note(s) Table b1 note a The substance bearing this CAS RN is a substance of unknown or variable composition, complex reaction products, or biological material. Return to table b1 note a referrer

All of the substances in the Tricyclic Sesquiterpenes and Triterpenoids Group have been included in surveys issued pursuant to section 71 of CEPA, with thujopsene, alpha-gurjunene, beta-patchoulene, beta-cedrene, T&T cedarwood oil, amboryl acetate, enoxolone, allantoin glycyrrhetinic acid, mimosa oil, ivy extract, and American ginseng extract not reported as being manufactured or imported above the reporting threshold of 100 kg in 2011. Alpha-cedrene and cedarwood oil are reported as being imported into Canada at quantities of between 100 kg and 1 000 kg; however, there were no reports of manufacture above the reporting threshold of 100 kg in 2011. Texan cedarwood oil is reported as being manufactured and imported into Canada at quantities of 277 kg and 200 kg, respectively, in 2011. The substances in the Tricyclic Sesquiterpenes and Triterpenoids Group are generally used as fragrances in cosmetics, natural health products (NHPs), non-prescription drugs (NPDs), cleaning products, and air fresheners. Some of them are also present in pest control products as formulants, and cedarwood oil is an active ingredient used only to manufacture pest control products intended for export out of Canada. In addition, some of them occur naturally in foods and are potentially used as food flavouring agents.

The ecological risks of the substances in the Tricyclic Sesquiterpenes and Triterpenoids Group were characterized using the ecological risk classification of organic substances (ERC) approach, which is a risk-based approach that employs multiple metrics for both hazard and exposure, with weighted consideration of multiple lines of evidence for determining risk classification. Hazard profiles are based principally on metrics regarding mode of toxic action, chemical reactivity, food web–derived internal toxicity thresholds, bioavailability, and chemical and biological activity. Metrics considered in the exposure profiles include potential emission rate, overall persistence, and long-range transport potential. A risk matrix is used to assign a low, moderate, or high level of potential concern for substances on the basis of their hazard and exposure profiles. Considering the outcome of the ERC analysis, the substances in the Tricyclic Sesquiterpenes and Triterpenoids Group are considered unlikely to be causing ecological harm.

Considering all available lines of evidence presented in this draft assessment, there is a low risk of harm to the environment from the 14 substances in the Tricyclic Sesquiterpenes and Triterpenoids Group. It is proposed to conclude that the 14 substances in the Tricyclic Sesquiterpenes and Triterpenoids Group do not meet the criteria under paragraph 64(a) or (b) of CEPA, as they are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.

For the human health risk assessment, 10 of the substances in this Group have been addressed under two subgroups owing to similarities in their chemical structure, properties, and/or toxicity, while the remaining 4 substances were addressed individually. An impact on human health from exposure to these substances from environmental media is not expected due to the low quantities reported in response to a survey issued pursuant to section 71 of CEPA or to the estimated exposures from environmental monitoring and modelling. Where applicable, exposures were characterized from the use of cosmetics, NPDs, and NHPs, from possible use as food flavouring agents, cleaning products, and air fresheners, and from the use of do-it-yourself (DIY) products containing the tricyclic sesquiterpenes and triterpenoids.

For the Tricyclic Sesquiterpene subgroup 1 (alpha-cedrene, thujopsene, alpha-gurjunene, beta-patchoulene, beta-cedrene, cedarwood oil, T&T cedarwood oil, and Texan cedarwood oil), hazard information for cedarwood oil was used to inform the human health risk assessment. Thujopsene and alpha-cedrene and beta-cedrene are identified as major components of cedarwood oil, T&T cedarwood oil, and Texan cedarwood oil. For the dermal route, the critical effect level was based on systemic effects (decreased thymus weights), whereas for the oral route and inhalation, it was based on thyroid hormone changes.

The margins of exposure (MOEs) for cedarwood oil from dermal exposure to massage oils, fragrances, deodorants/antiperspirants (solid), moisturizers (body and face), conditioners (leave-on), body exfoliants (children who are 14 to 18 years old), aftershave (face), after hair removal products (body), antiseptic skin cleansers (spray) [NHP] (children who are 2 to 8 years old, for situations of public health concern resulting in increased use), counterirritants (spray) [NHP] (children who are 9 to 18 years old), and irritation relief balms (NHP) are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. The MOEs for cedarwood oil from inhalation exposure to fragrances (children who are 2 to 3 years old) are also considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk.

Furthermore, the MOEs for daily dermal exposure from the use of cedarwood oil in DIY aroma diffusers / air fresheners, DIY massage oils, DIY body moisturizers, and DIY facial steamers/mists are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. The MOEs for daily inhalation exposure from the use of cedarwood oil in DIY aroma diffusers / air fresheners and DIY facial steamers/mists are also considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk.

There were no identified sources of exposure for the general population from thujopsene, alpha-gurjunene, beta-patchoulene, and beta-cedrene, and a qualitative approach to risk characterization was taken.

The MOE for T&T cedarwood oil from foods, which is based on its potential use as a food flavouring agent, is considered adequate to address uncertainties in the health effects and exposure data. There were no other identified sources of exposure for the general population from the substance; as a result, T&T cedarwood oil is considered to be of low concern for human health at current levels of exposure.

The MOEs for Texan cedarwood oil from daily dermal exposure to massage oils, fragrances, deodorants/antiperspirants (solid), and moisturizers (body and face) are considered potentially inadequate to address uncertainties in the health effects and exposure data used to characterize risk.

In addition, the dermal exposure to Texan cedarwood oil in DIY aroma diffusers / air fresheners, DIY massage oils, DIY body moisturizers, and DIY facial steamers/mists are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. The MOEs for Texan cedarwood oil from daily inhalation exposure to DIY aroma diffusers / air fresheners and DIY facial steamers/mists are considered potentially inadequate to address uncertainties in the health effects and exposure data used to characterize risk.

For amboryl acetate, health effects of concern were not identified, and there were no identified sources of exposure to the general population; as a result, amboryl acetate is considered to be of low concern for human health at current levels of exposure.

The Triterpenoid subgroup 2 consists of enoxolone and allantoin glycyrrhetinic acid. The critical health effect identified for enoxolone was developmental neurotoxicity. The MOEs for enoxolone from face moisturizers, body moisturizers (sprays and lotions), permanent hair dyes, sunscreens (creams) [NHP and NPD], analgesic patches (NHP) [children who are 13 years old and under], acne therapy (creams) [NHP], medicated skin care products (creams) [NHP], and licorice tea and black licorice candy are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. For allantoin glycyrrhetinic acid, there were no available empirical data. There were no identified sources of exposure of the general population to allantoin glycyrrhetinic acid; as a result, allantoin glycyrrhetinic acid is considered to be of low concern for human health at current levels of exposure.

For mimosa oil, the risk characterization of the main components, lupenone and lupeol, has been considered using health effects information on the analogue enoxolone. The critical health effect identified was developmental neurotoxicity. The MOEs for mimosa oil from fragrances (roll-on and spray), body moisturizers, face moisturizers, massage oils (children who are 1 year old and under), massage bars, sunless tanning products, facial makeup (liquid foundation), lipstick (children who are 8 years old and under), and sunscreens (lotions) [NHP] (children who are 3 years old and under and children who are 14 to 18 years old) are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. Furthermore, the MOEs between the critical effect level and the estimates of daily exposure from the use of mimosa oil in DIY aroma diffusers / air fresheners, DIY massage oils, and DIY body moisturizers are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk.

For ivy extract, the risk characterization of the main components, hederacoside C, hederagenin, and alpha-hederin, has been considered using health effects information on the analogue enoxolone. The critical health effect identified was developmental neurotoxicity. The MOEs for ivy extract from massage oils, body moisturizers, face moisturizers, facial makeup fixers (sprays), body exfoliants, and hair conditioners (leave-on) are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk. Furthermore, the MOEs between the critical effect level and the estimates of daily exposure from the use of ivy extract in DIY massage oils and DIY body moisturizers are considered potentially inadequate to account for uncertainties in the health effects and exposure data used to characterize risk.

For American ginseng extract, a read-across analogue, Asian ginseng (Panax ginseng), was used to inform the health effects assessment. Health effects of concern were not identified for American ginseng extract; as a result, American ginseng extract is considered to be of low concern for human health at current levels of exposure.

The human health assessment for each substance took into consideration those groups of individuals within the population in Canada who, due to greater susceptibility or greater exposure, may be more vulnerable to experiencing adverse health effects. Certain subpopulations are routinely considered throughout the assessment process, such as infants, children, and people of reproductive age. For instance, age-specific exposures are routinely estimated, and developmental and reproductive toxicity studies are evaluated for potential adverse health effects. These subpopulations with potential for higher exposure and those who may be more susceptible were taken into account in the human health risk assessment outcomes.

Considering all the information presented in this draft assessment, it is proposed to conclude that cedarwood oil, Texan cedarwood oil, enoxolone, mimosa oil, and ivy extract meet the criteria under paragraph 64(c) of CEPA, as they are entering or may enter the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health. Considering all the information presented in this draft assessment, it is proposed to conclude that alpha-cedrene, thujopsene, alpha-gurjunene, beta-patchoulene, beta-cedrene, T&T cedarwood oil, amboryl acetate, allantoin glycyrrhetinic acid, and American ginseng extract do not meet the criteria under paragraph 64(c) of CEPA, as they are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

Proposed overall conclusion

It is therefore proposed to conclude that cedarwood oil, Texan cedarwood oil, enoxolone, mimosa oil, and ivy extract meet one or more of the criteria set out in section 64 of CEPA, and that alpha-cedrene, thujopsene, alpha-gurjunene, beta-patchoulene, beta-cedrene, T&T cedarwood oil, amboryl acetate, allantoin glycyrrhetinic acid, and American ginseng extract do not meet any of the criteria set out in section 64 of CEPA.

The draft assessment and the risk management scope document for these substances are available on the Canada.ca (Chemical substances) website.

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.

Governor in Council appointment opportunities
Position	Organization	Closing date
Chairperson	Canada Deposit Insurance Corporation
Chairperson	Canada Industrial Relations Board
Vice-Chairperson	Canada Industrial Relations Board
Chairperson	Canada Infrastructure Bank
Director	Canada Lands Company Limited
President	Canada Water Agency
Chief Executive Officer	Canadian Accessibility Standards Development Organization
Assistant Chief Commissioner	Canadian Grain Commission
President	Canadian High Arctic Research Station
Chief Commissioner	Canadian Human Rights Commission
Permanent Member	Canadian Nuclear Safety Commission
Director	Canadian Tourism Commission
President	Canadian Tourism Commission
Chairperson	Civilian Review and Complaints Commission for the Royal Canadian Mounted Police
Vice-Chairperson	Civilian Review and Complaints Commission for the Royal Canadian Mounted Police
Director	Defence Construction (1951) Limited
Reviewer	Department of Citizenship and Immigration
Vice-Chairperson	Federal Public Sector Labour Relations and Employment Board
Chairperson	First Nations Infrastructure Institute
Director	First Nations Infrastructure Institute
Director (Federal)	Halifax Port Authority
Commissioner of Official Languages	Office of the Commissioner of Official Languages
Deputy Director of Public Prosecutions	Office of the Director of Public Prosecutions
Ombudsperson for the Department of National Defence and the Canadian Forces	Office of the Ombudsperson for the Department of National Defence and the Canadian Forces
Member	Payments in Lieu of Taxes Dispute Advisory Panel
Chief Public Health Officer	Public Health Agency of Canada
Principal	Royal Military College of Canada
Director	Sept-Îles Port Authority
Administrator	Ship-source Oil Pollution Fund and Fund for Railway Accidents Involving Designated Goods
Co-chair	Sustainable Jobs Partnership Council
Member	Sustainable Jobs Partnership Council
Chairperson	The Jacques-Cartier and Champlain Bridges Inc.
Secretary	The National Battlefields Commission
Member	Transportation Appeal Tribunal of Canada
Chairperson	VIA Rail Canada Inc.

DEPARTMENT OF HEALTH

Notice of intent to make a Ministerial Exemption Order to permit continued supply of naloxone kits on the Canadian market

Background

Naloxone kits

Naloxone is a life-saving medication that temporarily reverses the effects of opioid overdoses. Naloxone is critical for healthcare providers, community organizations and individuals across the country. Naloxone kits play an essential role in the response to the opioid crisis, and it is important that there be an uninterrupted supply of these products in Canada.

Naloxone kits are packaged, labelled and sold in Canada by various public and private sector stakeholders. Some of these kits are created by removing drugs, medical devices, and natural health products from their original packaging and relabelling them in a way that does not comply with the Food and Drug Regulations (FDR), the Medical Devices Regulations (MDR), and the Natural Health Products Regulations (NHPR). Additionally, some establishments that package, label, and sell naloxone kits may not hold the required establishment or site licences under the FDR, MDR, and NHPR.

Interim policy on the packaging, labelling and sale of naloxone kits

Health Canada published the Interim policy on the packaging, labelling and sale of naloxone kits (interim policy) on December 9, 2024, and committed to revisiting this policy in the fall of 2025, or earlier as needed. The interim policy outlined conditions that must be met for Health Canada to exercise discretion with enforcing certain packaging, labelling and sale requirements under the FDR and MDR.

Health Canada has been engaging with provinces and territories to learn about their activities related to naloxone kits, how they relate to the regulations, and assess if there are associated health and safety risks. Further consultations are needed to determine the impacts of the interim policy on all stakeholders and to identify relevant considerations for the implementation of more long-term measures like a Ministerial Exemption Order.

Ministerial exemption authority

Health Canada is proposing to make a Ministerial Exemption Order (EO), pursuant to subsection 30.05(1) of the Food and Drugs Act (the Act) whereby the Minister may exempt a class of foods, therapeutic products, persons or activities from the application of all or any of the provisions of Part I and section 37 of the Act, or the regulations.

Under subsection 30.05(2) of the Food and Drugs Act, the Minister of Health may make a ministerial class exemption order only if they believe on reasonable grounds that:

It is necessary for a health or safety purpose or is otherwise in the public interest; and
Having regard to its benefits and conditions, it is unlikely to result in
- (a) unacceptable health, safety or, if applicable, environmental risks, or
- (b) an unacceptable degree of uncertainty respecting health, safety or, if applicable, environmental risks.

Proposed Ministerial Exemption Order

Objective

The proposed EO would address feedback received on the interim policy and allow for the transition to a formal regulatory instrument. Health Canada’s objective is to help ensure continued access to naloxone kits on the Canadian market, while maintaining the quality, safety, efficacy and traceability of these kits.

Proposal

Scope

The proposed EO would

Define what classes of products, persons, and activities are subject to the EO (e.g. packaging, labelling, and selling).
Exclude naloxone kits prepared using authorized products kept in their original Health Canada approved packaging and labelling, and that are imported, packaged, labelled and sold by persons holding applicable establishment and site licences.
Require importers of products in naloxone kits and subject to the EO to hold relevant establishment and site licences.

Exemptions

To help ensure the continued supply of naloxone kits, the EO would include exemptions from the application of certain provisions in the FDR, MDR and NHPR, such as exemptions from requirements for product authorizations, as well as establishment and site licences, as some stakeholders may not be able to meet all current regulatory requirements. The exemptions would only apply if certain conditions are met.

Conditions

Building on the interim policy, Health Canada is proposing to put in place conditions to maintain important oversight and safety requirements on the packaging, labelling, and sale of naloxone kits. The conditions would be focused on the quality, safety, efficacy, and traceability of these kits in Canada, which is important to mitigate possible health and safety risks to people in Canada.

The proposed conditions include those already outlined in the Interim policy on the packaging, labelling and sale of naloxone kits, and some additional conditions that build on the interim policy to help maintain health and safety. For example, conditions for natural health products, such as antiseptic wipes that may be included in naloxone kits, which were not captured under the interim policy, would be added. Further, proposed conditions to facilitate Health Canada’s oversight of the safety of these products, such as the oversight over possible recalls of naloxone kit products, would also be included.

Overview of the proposed conditions:

To help ensure the safety, quality and efficacy of products used in the naloxone kit, all components (e.g. vials, syringes, etc.) must be products authorized by Health Canada under the Act. Class I medical devices must be sourced from someone with a valid Medical Device Establishment Licence (MDEL).
Sufficient information in both official languages must appear on kit labels and on product labels within the kit. Instructions for use must be included so that the naloxone can be administered safely and effectively, and the information on the label should allow for kits and products within the kits to be traced.
Distribution records and recall procedures must be maintained to allow for rapid and effective recalls of unsafe or ineffective kits, or products within the kits, should an issue arise.
Kits and products within the kits must be packaged, stored, and transported under appropriate conditions to preserve their safety, quality, and efficacy.
Adverse events and safety incidents must be reported to the original manufacturer of products included in kits so that they can process the information as part of their post-market surveillance systems.
Those subject to the EO must provide an attestation within 30 days after starting to conduct activities to allow Health Canada to maintain awareness and oversight of who is packaging, labelling and storing naloxone kits and where these activities are taking place.

Coming into force

The EO would come into force once published in the Canada Gazette, Part II (expected for June 2025).

Additional time may be allocated for stakeholders to comply with the proposed conditions of the EO.

Health Canada’s intention is for the EO to be in place on a temporary basis with the goal of reassessing whether the EO should remain or be updated, repealed or incorporated into our regulations.

Feedback and public comments

Health Canada is interested to hear from people in Canada, including on the following questions:

As a packager, labeller or seller of naloxone kits, what would be the impact of the proposed conditions on your current activities related to packaging, labelling, and selling of naloxone kits?

As a packager, labeller or seller of naloxone kits, in what ways would you need to adapt your current activities to meet these conditions?

As a packager, labeller or seller of naloxone kits, are there any conditions mentioned in this notice of intent that would require a transition timeline? If so, what would be an appropriate timeline?

What effect, if any, would the conditions have on the supply of naloxone kits in Canada?

What else should Health Canada consider when developing the Exemption Order?

Public comment period

This consultation will be open for 30 days, ending March 31, 2025. Interested parties may submit written comments, in English or in French, by email to prsd-questionsdspr@hc-sc.gc.ca with the following title in the subject line: “Notice of Intent — Consultation on Potential Ministerial Exemption Order regarding Naloxone Kits” or by mail to Jillian Andrews, Acting Associate Director, Compliance Policy and Regulatory Affairs, Policy and Regulatory Strategies Directorate, 200 Eglantine Driveway, Ottawa, Ontario K1A 0K9.

Should you have additional questions or would like additional information about the proposed exemption order and conditions, Health Canada is planning to hold a stakeholder engagement session on March 20, 2025. If you would like to participate please send an email to prsd-questionsdspr@hc-sc.gc.ca with “engagement session” in the subject line. The session will only be scheduled if there is enough interest.

Language selection

Search